Core Viewpoint - Ultragenyx Pharmaceutical Inc. is recognized as one of the best revenue growth stocks, with a focus on developing therapies for rare genetic diseases, particularly through its resubmission of the Biologics License Application for UX111 AAV9 gene therapy targeting Sanfilippo syndrome type A [1][3]. Group 1: Company Developments - The company resubmitted its Biologics License Application (BLA) to the U.S. FDA on January 30, seeking accelerated approval for UX111 AAV9 gene therapy [1]. - The resubmitted BLA addresses previous concerns from the FDA, with an anticipated review period of up to six months, expected to conclude in the third quarter [3]. - If approved, UX111 will be the first therapy available for Sanfilippo syndrome type A [3]. Group 2: Analyst Ratings and Market Position - Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ultragenyx Pharmaceutical with a price target of $50 [3]. - In the past month, Leerink Partners also issued a Buy rating, while Wedbush reiterated a Hold rating on the stock [3]. - The company’s product portfolio includes therapies such as Crysvita, Mepsevii, Dojolvi, and Evkeeza, emphasizing its commitment to rare and ultra-rare genetic diseases [3].

Group 1 - Legend Biotech Corp (NASDAQ:LEGN) is recognized as one of the 13 Best Revenue Growth Stocks to buy currently [1] - The company appointed Robin Meng, chairman and executive director of major shareholder GenScript, as a Class III director, replacing Li Zhu [1] - Directors Li Zhu and Yau Wai Man Philip resigned from the board, with the company stating that these departures were not related to any operational or policy disputes [3] Group 2 - H. C. Wainwright lowered the price target for Legend Biotech's stock from $60 to $50, while TD Cowen downgraded the stock from Buy to Hold with a price target of $21 [3] - Legend Biotech reported preliminary net trade sales of approximately $555 million for its CARVYKTI multiple myeloma cell therapy for the quarter ended December 31, 2025 [3] - The company is engaged in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications [3]

Core Insights - Wave Life Sciences Ltd (NASDAQ:WVE) is recognized as one of the 13 best revenue growth stocks to buy currently [1] - The company regained full rights to WVE-006, a potential treatment for alpha-1 antitrypsin deficiency, from GSK, addressing a significant unmet medical need [1][3] - The disease affects approximately 200,000 individuals in the U.S. and Europe, with no approved therapies available for its lung and liver manifestations [1] Company Strategy - Wave Life Sciences is accelerating its strategy for WVE-006 and plans to engage with the U.S. Food and Drug Administration regarding a potential accelerated approval pathway, with regulatory feedback anticipated by mid-2026 [3] - The collaboration with GSK allows Wave Life to be eligible for up to $2.8 billion in various milestones and tiered royalties [3] - The company's cash runway is projected to sustain operations until the third quarter of 2028 [3] Market Position - Analyst Yun Zhong from Wedbush has maintained a Buy rating on Wave Life's stock, setting a price target of $33 [3] - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA-based genetic medicines utilizing its proprietary PRISM platform for stereopure oligonucleotides [3]

Core Insights - Savant Capital LLC increased its holdings in BioMarin Pharmaceutical Inc. by 54.4% in Q3, owning 82,827 shares valued at $4,486,000 after purchasing an additional 29,174 shares [2] - Other institutional investors also made significant changes, with Financiere des Professionnels acquiring a new stake worth approximately $1,047,000, and Jump Financial LLC increasing its stake by 530.3% [3] - The majority of BioMarin's stock, 98.71%, is owned by hedge funds and institutional investors [3] Institutional Activity - AQR Capital Management boosted its holdings by 90.7%, now owning 5,580,573 shares valued at $306,429,000 after an additional purchase of 2,654,768 shares [3] - Federated Hermes Inc. increased its stake by 292.6%, owning 278,315 shares valued at $15,074,000 after purchasing an additional 207,430 shares [3] - Mediolanum International Funds Ltd raised its stake by 56.2%, now holding 137,675 shares valued at $7,437,000 after acquiring an additional 49,534 shares [3] Analyst Ratings - Stifel Nicolaus maintained a "hold" rating with a price target of $61.00, down from $73.00 [4] - Morgan Stanley decreased its target price from $104.00 to $98.00 while maintaining an "overweight" rating [4] - The consensus rating for BioMarin Pharmaceutical is "Moderate Buy" with an average price target of $88.29 [4] Stock Performance - BioMarin shares opened at $58.13, with a 52-week low of $50.76 and a high of $73.51 [5] - The company has a market cap of $11.17 billion, a price-to-earnings ratio of 21.85, and a price-to-earnings-growth ratio of 0.63 [5] - BioMarin's quick ratio is 3.10, current ratio is 4.83, and debt-to-equity ratio is 0.10 [5] Company Overview - BioMarin Pharmaceutical specializes in therapies for rare genetic and metabolic diseases, focusing on unmet medical needs through enzyme replacement therapy, small molecule pharmacological chaperones, and gene therapy technologies [6] - The company is headquartered in Novato, California, with R&D facilities in the U.S. and Europe [6] - BioMarin's commercial portfolio includes several approved therapies targeting inherited disorders [7]

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against PomDoctor Ltd. (NASDAQ: POM) on behalf of investors who purchased securities between October 9, 2025, and December 11, 2025, alleging that the company misled investors regarding its business operations [1]. Group 1: Allegations Against PomDoctor Ltd. - The lawsuit claims that PomDoctor was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [1]. - It is alleged that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [1]. - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [1]. - As a result of these actions, the positive statements made by the defendants about PomDoctor's business, operations, and prospects were materially misleading and lacked a reasonable basis [1]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their motions with the court by April 7, 2026 [1]. - A lead plaintiff acts on behalf of other class members in directing the litigation, but participation is not required to be eligible for recovery [1]. - All representation in this case is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [1].

Core Viewpoint - Lexicon Pharmaceuticals has successfully closed a public offering of 32 million shares of common stock and a concurrent private placement of 22.4 million shares of common stock and 367,145 shares of Series B Convertible Preferred Stock, with the offerings closing on February 2, 2026 [1]. Group 1: Offering Details - The public offering price for the common stock was set at $1.30 per share, while the Series B Convertible Preferred Stock was sold at $65 per share [1]. - An additional 30-day option has been granted to underwriters to purchase up to 4.8 million shares of common stock at the public offering price [2]. - The Private Placement Purchaser has the option to buy an additional 94,855 shares of Series B Convertible Preferred Stock, convertible into 4,742,744 shares of common stock, at the same price of $65 per share [2]. Group 2: Use of Proceeds - Lexicon intends to utilize the net proceeds from the offerings for the continued research and development of its drug candidates, as well as for working capital and other general corporate purposes [4]. Group 3: Regulatory Information - A shelf registration statement related to the public offering was filed with the SEC on August 2, 2024, and was declared effective on August 15, 2024 [5]. - The shares issued in the private placement have not been registered under the Securities Act and may not be offered or sold in the U.S. without proper registration or exemption [5]. Group 4: Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing medicines that transform patients' lives, with a pipeline targeting neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolism, and other indications [7].

As filed with the Securities and Exchange Commission on February 6, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 2834 92-1954864 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NeOnc Technologies Holdings, Inc. (Exact name of registrant as specified in its charter) Identification Number) 23975 ...

Core Viewpoint - Azitra, Inc. has adjourned its Special Meeting originally scheduled for February 6, 2026, due to insufficient shareholder participation, with a new date set for March 6, 2026, to solicit additional votes on key proposals [1]. Group 1: Special Meeting Details - The Special Meeting was adjourned because only approximately 13% of the outstanding shares entitled to vote were represented, falling short of the required 33 1/3% quorum [1]. - The Reconvened Special Meeting will take place on March 6, 2026, at 11:00 a.m. Eastern Time, and will continue to be held in a virtual format [1]. - Stockholders are encouraged to vote their shares before the new deadline of March 6, 2026, at 10:59 a.m. Eastern Time [1]. Group 2: Proposals for Vote - Proposal One seeks approval for the issuance of more than 19.99% of the company's outstanding shares, which includes shares underlying warrants as per the Securities Purchase Agreement with Alumni Capital LP [1]. - Proposal Two allows for the adjournment of the Special Meeting if necessary to solicit additional proxies if there are insufficient votes [1]. Group 3: Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on innovative therapies for precision dermatology, with its lead program, ATR-12, targeting Netherton syndrome, a rare skin disease [1]. - The company also has an advanced program, ATR-04, aimed at treating EGFR inhibitor-associated rash, which affects approximately 150,000 people in the U.S. [1]. - Azitra's programs utilize a proprietary platform of engineered proteins and topical live biotherapeutic products, supported by artificial intelligence and machine learning technology [1].

Core Insights - Denali is focused on delivering biotherapeutics to the entire body, including the brain, for individuals with serious diseases [2][3] Group 1: Company Overview - Denali was founded to harness the potential of biotherapeutics for comprehensive treatment [2] - The company is presenting highlights of its enzyme transport vehicle technology at the WORLDSymposium in San Diego [1] Group 2: Technology Introduction - Denali has engineered the binding of the Transferrin receptor into its TransportVehicle [2]

Group 1 - Agomab Therapeutics shares experienced an approximately 8% decline during their Nasdaq debut [1] - The company, based in Belgium, is currently valued at $716.4 million following its initial public offering [1]